近日消息，駕玉生物醫(yī)藥有限公司（駕玉生物）宣布完成B輪融資。本輪融資由香港知名投資機(jī)構(gòu)鼎珮集團(tuán)（VMS Group）領(lǐng)投，瑞伏醫(yī)療創(chuàng)投基金(Panacea Venture)跟投。本輪融資將用于新增生物藥GMP檢測(cè)業(yè)務(wù)的儀器設(shè)備、試劑耗材購(gòu)買(mǎi)，人員招聘及公司運(yùn)營(yíng)，技術(shù)專(zhuān)利購(gòu)買(mǎi)等費(fèi)用。 

駕玉生物創(chuàng)始人、董事長(zhǎng)、CEO林巧（Claudia Lin）博士表示：在過(guò)去5年內(nèi)，駕玉有幸服務(wù)了國(guó)內(nèi)外多于50家頗有成就的生物制藥領(lǐng)軍公司。此次B輪融資在嚴(yán)峻的生物醫(yī)藥行業(yè)整頓及其它不利因素大環(huán)境下，駕玉生物能再一次得到有國(guó)際化視野的生物創(chuàng)新藥研發(fā)及產(chǎn)業(yè)化專(zhuān)業(yè)投資機(jī)構(gòu)VMS Group和Panacea Venture的認(rèn)可，為駕玉下一階段的檢測(cè)業(yè)務(wù)快速發(fā)展如虎添翼，在已有的生物大分子藥包括細(xì)胞基因治療產(chǎn)品的國(guó)際化GMP標(biāo)準(zhǔn)全方位檢測(cè)業(yè)務(wù)奠定扎實(shí)的基礎(chǔ)。此輪融資建立在駕玉與國(guó)際生物醫(yī)藥CXO巨頭查爾斯河的戰(zhàn)略合作基礎(chǔ)上、充分結(jié)合國(guó)際大公司在行業(yè)中的領(lǐng)先地位與駕玉在中國(guó)本土藥監(jiān)環(huán)境下的經(jīng)驗(yàn)，在駕玉開(kāi)辟的獨(dú)特生物藥質(zhì)量服務(wù)賽道為中國(guó)生物藥創(chuàng)新藥走向國(guó)際先進(jìn)市場(chǎng)有著獨(dú)特及關(guān)鍵的意義。我堅(jiān)信、接下來(lái)的5年是駕玉在這個(gè)稀缺領(lǐng)域細(xì)分賽道做大做全，始終保持國(guó)際化的GMP質(zhì)量服務(wù)標(biāo)準(zhǔn)，不斷緊跟高端生物藥國(guó)際國(guó)內(nèi)的研發(fā)步伐，為中國(guó)及世界人民的健康不斷努力的新階段，在新老合作伙伴的支持下，我們對(duì)未來(lái)充滿(mǎn)信心。      

鼎珮集團(tuán)（VMS）董事總經(jīng)理及醫(yī)療健康投資主管、瑞伏醫(yī)療創(chuàng)投合伙人伍兆威先生表示：駕玉生物為全球的高端生物制藥公司，特別是細(xì)胞和基因療法（C&GT）公司，提供端到端的質(zhì)量和檢測(cè)技術(shù)服務(wù)，在蓬勃發(fā)展的生物質(zhì)量和檢測(cè)外包服務(wù)領(lǐng)域中占據(jù)領(lǐng)導(dǎo)者的位置。我們很榮幸能領(lǐng)投本輪融資，并致力于投資具有突破性技術(shù)和高增長(zhǎng)潛力的公司。 我們有信心在創(chuàng)始團(tuán)隊(duì)的帶領(lǐng)下，公司將持續(xù)快速的發(fā)展，在中國(guó)乃至全球的生物制品質(zhì)量外包服務(wù)市場(chǎng)中大放異彩。

Shanghai-Suzhou – Suzhou, China, Hong Kong and Shanghai, September 8, 2022 – Jade Biomedical Co. Ltd., (“Jade Bio”) a Suzhou based CXO biologics service company proving contract services for companies developing biologic therapeutics from its Contract Quality, Bio-CQO? and Contract Testing Laboratories (CTL), Bio-Pacific Laboratories? announced the completion of Series B Financing.  The funds will be used for the expansion of its biologics testing (Bio-Pacific Laboratories, BPL) services and operations.

VMS Led the round, with participation from Panacea Healthcare.

Founded in 2017 by China National Innovation Expert, a US bio-pharmaceutical GMP quality management veteran Dr. Claudia Qiao Lin, Jade Bio was the first ever to propose and register the trademark for a new business model, Bio-CQO?, quality contracting service for biological products.  In the past 5 years, Jade Bio has successfully helped leading Chinese and US companies in a repertoire of GMP quality service areas contributing to successful IND and BLA filings on more than 50 projects covering monoclonal antibody, ADC, CAR-T and other CGT, mRNA products. 

Jade Bio has developed, validated, and holds ownership of proprietary technologies, for advanced test methods (e.g. RCL, Replication Competent Lentivirus), all of which have been used in successful product regulatory submissions in China and the U.S.  In addition, Jade provides a one-stop biological sample import and export service (inclusive of cold-chain management solutions) by working closely with local and regional government custom officials and hubs, removing logistics obstacles in an ever-expanding globalization trend between Chinese and global companies. 

Dr. Claudia Lin, founder, chairman and CEO of Jade Bio, says: “This successful Series B Financing from two influential healthcare investment firms, VMS and Panacea， in the midst of an industry market correction with limited financing opportunities further establishes and enhances Jade Bio’s strong position for the continuation of its upward trajectory, expansion of service offerings, and market reach in China and beyond.  The financing builds upon Jade’s strategic collaboration with Charles River to combine Charles River’s industry expertise with JADE’s deep knowledge of local regulatory environments, providing clients with a leading solution. With our partners, we firmly believe that the unique expertise and position Jade Bio has gained in addressing one of the major obstacles that limit initial and long-term product success, i.e. lack of manufacturing quality and GMP compliance, will enable more of the Chinese biologics companies to not only launch high quality products with clinical benefits to the Chinese people, but also expand into US and EU markets.” 

Andrew Ng, Head of Healthcare of VMS Group and Investment Partner of Panacea Venture says: “Jade Bio provides premium end-to-end quality and testing technology services for top-tier biopharmaceutical companies, especially for those in the cell and gene therapy industry. Jade is in a leading position of the booming field of biological quality and testing outsourcing services. We are honored to lead this financing round, and we are committed to investing in companies with breakthrough technologies and high growth potential. We are confident that Jade will continue to develop rapidly under the leadership of the founding team.”